Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4764549 | 1.00 | KMT2A (0.64) | KMT2AMEN1PTGS1PTGS2ALDH1A1 | |
| SCHEMBL4769469 | 1.00 | KMT2A (0.64) | KMT2AMEN1PTGS1PTGS2ALDH1A1 | |
| SCHEMBL4767023 | 0.82 | ESR1 (0.54) | KMT2AALDH1A1 | |
| SCHEMBL4771223 | 0.82 | ESR1 (0.54) | KMT2AALDH1A1 | |
| SCHEMBL27662344 | 0.82 | ESR1 (0.54) | KMT2AALDH1A1 | |
| SCHEMBL4776015 | 0.80 | HCAR2 (0.46) | KMT2APTGS1PTGS2ALDH1A1LMNA | |
| SCHEMBL16993624 | 0.80 | HCAR2 (0.46) | KMT2APTGS1PTGS2ALDH1A1LMNA | |
| SCHEMBL19924995 | 0.80 | HCAR2 (0.46) | KMT2APTGS1PTGS2ALDH1A1LMNA | |
| SCHEMBL290694 | 0.80 | MMP8 (0.56) | KMT2AMEN1ALDH1A1TSHRSLC6A3 | |
| SCHEMBL4773472 | 0.79 | L3MBTL1 (0.45) | KMT2AMEN1ALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200061225-A1 | ALDEHYDE SCAVENGER AND METHOD FOR REMOVING ALDEHYDES | TOSOH CORPORATION (JP) | 2020-02-27 | — | — | US | claimed |
| EP-3564334-A1 | ALDEHYDE SCAVENGER AND ALDEHYDE REMOVAL METHOD | Tosoh Corporation (JP) | 2019-11-06 | — | — | EP | claimed |
| CN-109963922-A | Aldehyde agent for capturing and aldehyde minimizing technology | 东曹株式会社 | 2019-07-02 | — | — | CN | claimed |
| EP-0188805-A1 | 1,3-Dithiole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1986-07-30 | — | — | EP | claimed |
| CN-109963922-B | Aldehyde scavenger and method for removing aldehyde | 东曹株式会社 | 2022-09-23 | — | — | CN | disclosed |
| EP-3564334-A1 | ALDEHYDE SCAVENGER AND ALDEHYDE REMOVAL METHOD | Tosoh Corporation (JP) | 2019-11-06 | — | — | EP | disclosed |
| CN-109963922-A | Aldehyde agent for capturing and aldehyde minimizing technology | 东曹株式会社 | 2019-07-02 | — | — | CN | disclosed |
| EP-3051946-A1 | USE OF SUBSTITUTED DIHYDRO-OXINDOLYL SULFONAMIDES, OR THE SALTS THEREOF, FOR INCREASING THE STRESS TOLERANCE OF PLANTS | Bayer CropScience Aktiengesellschaft (DE) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015049351-A1 | USE OF SUBSTITUTED DIHYDRO-OXINDOLYL SULFONAMIDES, OR THE SALTS THEREOF, FOR INCREASING THE STRESS TOLERANCE OF PLANTS | BAYER CROPSCIENCE AG (DE) | 2015-04-09 | — | — | WO | disclosed |
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-8598162-B2 | Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-12-03 | — | — | US | disclosed |
| CN-103351315-A | General preparation method of sulfonyl chloride | UNIV BEIJING CHEMICAL | 2013-10-16 | — | — | CN | disclosed |
| US-6486180-B1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-11-26 | — | — | US | disclosed |
| EP-0650476-B1 | PERIPHERAL VASODILATING AGENT CONTAINING N-ACYLATED 4-AMINO PIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS | OTSUKA PHARMA CO LTD (JP) | 2002-06-26 | — | — | EP | disclosed |
| CN-1330661-A | Procollagen C-proteinase inhibitors | HOFFMANN LA ROCHE (CH) | 2002-01-09 | — | — | CN | disclosed |
| US-6331541-B1 | TREATING ASTHMA, ALLERGIC RHINITIS, ATOPIC DERMATITIS AND INFLAMMATORY BOWEL DISEASES | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2001-12-18 | — | — | US | disclosed |
| EP-0650476-A1 | PERIPHERAL VASODILATING AGENT CONTAINING N-ACYLATED 4-AMINO PIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-05-03 | — | — | EP | disclosed |
| WO-1994022826-A1 | PERIPHERAL VASODILATING AGENT CONTAINING N-ACYLATED 4-AMINO PIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-13 | — | — | WO | disclosed |
| US-RE31343-E | STABILIZERS FOR POLYMERS | CIBA-GEIGY CORPORATION (US) | 1983-08-09 | — | — | US | disclosed |
| US-RE31342-E | STABILIZERS FOR POLYMERS | CIBA-GEIGY CORPORATION (US) | 1983-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | GRIN2C, GRIN2B, PMP22 | KMT2A 480/4885MEN1 2715/4885PTGS1 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.